We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NOMA:NASDAQNOMADAR Corp. Analysis

Data as of 2026-08-02 - not real-time

$3.01

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The stock is trading below its short‑term moving average while the medium‑term average remains above the long‑term average, underscoring a bearish alignment. Momentum indicators show a neutral RSI that is not yet in oversold territory. A modest bullish MACD crossover is present, but both lines sit in negative territory, limiting the upside. Trading volume has been on a downward trajectory, reflecting waning market participation. Intraday price action is confined between a clear support level near the lower end of the recent range and a resistance ceiling just above the current price. The asset exhibits elevated short‑term volatility and a slightly negative beta, suggesting limited correlation with broader market moves.
Fundamentally, the company reports modest revenue growth and persistently negative operating margins. Earnings are absent, resulting in a price‑to‑book multiple that is well above industry norms and a price‑to‑sales ratio that signals extreme overvaluation. Cash flow generation is negative, while free cash flow remains marginal, raising concerns about sustainability. The balance sheet shows debt that dwarfs equity, and the historical drawdown has been severe. The market sentiment gauge is perched in the extreme greed zone, a contrast to the underlying financial weakness. Combined, these factors point to heightened risk and limited upside potential.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • price below short‑term SMA
  • declining volume
  • overvalued multiples

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • potential for modest recovery if cash burn slows
  • persistent negative earnings
  • high volatility

Long Term

> 3 years
Neutral
Model confidence: 4/10

Key Factors

  • structural challenges in business model
  • possible upside from brand licensing
  • ongoing debt burden

Key Metrics & Analysis

Financial Health

Revenue Growth116.00%
ROE-80.79%
ROA-20.90%
Debt/Equity30.92
P/B Ratio4.3
Op. Cash Flow$-1165777
Free Cash Flow$46.2K

Technical Analysis

TrendBearish
RSI45.3
Support$2.87
Resistance$3.88
MA 20$3.12
MA 50$3.37
MA 200$4.66
MACDBullish
VolumeDecreasing
Fear & Greed Index92.88

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta-0.13
Volatility115.98%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.